ponatinib
takeda
['ponatinib', 'cml', 'emergent ']
optic trial evaluating dynamic dosing of ponatinib in tx-resistant cml. starting at 45 mg seems to be more effective but slightly more toxic. but monitoring of co-morbidities and reduce dose to responders is important! #ash22 
Assistant Professor at UNC Eshelman School of Pharmacy. #adherence, #leukemia, #globalhealth, #access, #impsci, #equity